Evaluation of Combined Live, Attenuated Respiratory Syncytial Virus and Parainfluenza 3 Virus Vaccines in Infants and Young Children

Robert B. Belshe(University of Missouri–St. Louis), Frances K. Newman(Saint Louis University), Edwin L. Anderson(Saint Louis University), Peter F. Wright(Vanderbilt University), Ruth A. Karron(Johns Hopkins University), Sharon J. Tollefson(Vanderbilt University), Frederick W. Henderson(University of North Carolina at Chapel Hill), H. Cody Meissner(Tufts Medical Center), Shabir A. Madhi(University of the Witwatersrand), Don Roberton(The University of Adelaide), Helen Marshall(The University of Adelaide), Richard Loh(Princess Margaret Hospital for Children), Peter D. Sly(Princess Margaret Hospital for Children), Brian R. Murphy(National Institutes of Health), Joanne M. Tatem(Pearl River Community College), Valerie B. Randolph(Pearl River Community College), Jill Hackell(Pearl River Community College), William C. Gruber(Princess Margaret Hospital for Children), Theodore F. Tsai(Pearl River Community College)
The Journal of Infectious Diseases
December 10, 2004
10.1086/425981
Cited by 76Open Access
Full Text

Abstract

We evaluated a combination respiratory syncytial virus (RSV) and parainfluenza 3 virus (PIV3) live, attenuated intranasal vaccine for safety, viral replication, and immunogenicity in doubly seronegative children 6-18 months old. RSV cpts-248/404 and PIV3-cp45 vaccines were combined in a dose of 10(5) plaque-forming units of each per 0.5-mL dose and compared with monovalent vaccines or placebo. The virus shedding pattern of RSV was not different between monovalent RSV cpts-248/404 vaccine and combination vaccine. Modest reductions in the shedding of PIV3-cp45 vaccine virus were found after the administration of RSV cpts-248/404 and PIV3-cp45 vaccine, relative to monovalent PIV3 vaccine; 16 (76%) of 21 children given combination vaccine shed PIV3-cp45 versus 11 (92%) of 12 of those given monovalent PIV3 vaccine. Both vaccines were immunogenic, and antibody responses were similar between the monovalent groups and the combination group. Combined RSV/PV3 vaccine is feasible for simultaneous administration, and further studies are warranted.

Related Papers

No related papers found

Powered by citation graph analysis